The
Australian TGA has issued a document titled “Additional safety protections
relating to COVID-19 for faecal microbiota transplant (FMT) products.”
The
Therapeutic Goods Administration (TGA) is providing advice on safety
protections to faecal microbiota transplant (FMT) providers since there is the
potential to transmit the SARS-CoV-2 virus via FMT through shedding in stool.
FMT
products comprise, contain, or are derived from donated human stool and are
introduced into a recipient person for a therapeutic use. Human stool is
collected from a screened donor by defaecation. This stool is then processed
into an FMT product and provided to the recipient via enema, colonoscopy,
nasoenteric tube, or orally (e.g. capsules).
This
advice follows a recent safety alert from the US FDA that highlighted the
additional safety precautions that should be in place for COVID-19 disease
screening of potential stool donors for FMT products in order to prevent the
spread of the SARS-CoV-2 virus.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources